SCHEMBL6885293

SCHEMBL6885293

C=C(C)/N=C\C(C)=C/N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12524755 0.82
SCHEMBL12021528 0.78
SCHEMBL13159697 0.77
SCHEMBL14392654 0.77
SCHEMBL13960538 0.75
SCHEMBL13960537 0.75
SCHEMBL13960248 0.75
SCHEMBL23731133 0.75
SCHEMBL17722997 0.75 TDP1 (0.35)
SCHEMBL22968633 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4116294-A1 BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF HELIOEAST PHARMACEUTICAL CO., LTD. (CN) 2023-01-11 EP disclosed
US-20170002269-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2017-01-05 US disclosed
US-20160298033-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2016-10-13 US disclosed
US-20160115177-A1 HIGHLY POTENT INHIBITORS OF PORCUPINE THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-04-28 US disclosed
US-20160060530-A1 DEVICE CONTAINING A LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2016-03-03 US disclosed
US-8945420-B2 Liquid crystal display and liquid crystalline medium MERCK PATENT GMBH (DE) 2015-02-03 US disclosed
US-20140128390-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-05-08 US disclosed
US-8551359-B2 Liquid-crystalline compounds and liquid-crystalline media MERCK PATENT GMBH (DE) 2013-10-08 US disclosed
EP-2225211-B1 HERBICIDAL PYRIDAZINONE DERIVATIVES DU PONT (US) 2013-10-02 EP disclosed
WO-2012170867-A1 NOVEL COMPOUNDS AS MODULATORS OF GPR-119 RHIZEN PHARMACEUTICALS SA (CH) 2012-12-13 WO disclosed
WO-2012127393-A1 COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE NOVARTIS AG (CH) 2012-09-27 WO disclosed
EP-1966208-B1 (1-AZA-BICYCLO[3.3.1]NON-4-YL)-[5-(1H-INDOL-5-YL)-HETEROARYL]-AMINES AS CHOLINERGIC LIGANDS OF THE N-AChR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS NOVARTIS AG (CH) 2011-11-02 EP disclosed
EP-2354141-A1 (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders. Novartis AG (CH) 2011-08-10 EP disclosed
WO-2011036167-A1 USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS NOVARTIS AG (CH) 2011-03-31 WO disclosed
WO-2009012277-A1 METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-22 WO disclosed
WO-2008045945-A1 BENZINDOLE DERIVATIVES AND METHOD OF TREATING HIV/AIDS GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2008-04-17 WO disclosed
EP-1237155-B1 Optical recording film, method for manufacturing the same, optical recording medium, method for manufacturing the same, optical recording method, information recording/reproducing apparatus, information reproducing/recording method, computer system and video signal recording/reproducing system MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2007-11-14 EP disclosed
WO-2007068475-A1 (1-AZA-BICYCLO[3.3.1] N0N-4-YL)-[5-(IH-INDOL-5-YL)-HETEROARYL]-AMINES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS NOVARTIS AG (CH) 2007-06-21 WO disclosed
WO-2007068476-A1 [ (1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. NOVARTIS AG (CH) 2007-06-21 WO disclosed